ArticleCancer2023

Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.

Naresh Bumma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.